Vanda Pharma discloses 2024 bonuses, 2025 salaries, and RSU grants for NEOs

Vanda Pharmaceuticals Inc.

CEO Polymeropoulos: 2024 bonus $947,928; 2025 base salary $965,655; target bonus 80%; 450,000 RSUs.
CFO Moran and three SVPs: 2024 bonuses $309,181–$320,040; 2025 base $559,935–$579,600; 45% target; 125,000 RSUs each.
All RSUs vest in four equal annual installments commencing March 1, 2026.
Compensation Committee considered peer-group analysis by Willis Towers Watson before approving.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.